161 related articles for article (PubMed ID: 24440299)
1. Discovery and optimization of 5-(2-((1-(phenylsulfonyl)-1,2,3,4-tetrahydroquinolin-7-yl)oxy)pyridin-4-yl)-1,2,4-oxadiazoles as novel gpr119 agonists.
Wang Y; Yu M; Zhu J; Zhang JK; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Liu JJ; Coward P
Bioorg Med Chem Lett; 2014 Feb; 24(4):1133-7. PubMed ID: 24440299
[TBL] [Abstract][Full Text] [Related]
2. Discovery and optimization of arylsulfonyl 3-(pyridin-2-yloxy)anilines as novel GPR119 agonists.
Zhang JK; Li AR; Yu M; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Eksterowicz J; Coward P; Liu JJ
Bioorg Med Chem Lett; 2013 Jun; 23(12):3609-13. PubMed ID: 23648181
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of N-(3-(1,3-dioxo-2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-4-yloxy)phenyl)benzenesulfonamides as novel GPR119 agonists.
Yu M; Ken Zhang J; Wang Y; Zhu J; Kayser F; Medina JC; Siegler K; Conn M; Shan B; Grillo MP; Coward P; Jim Liu J
Bioorg Med Chem Lett; 2014 Jan; 24(1):156-60. PubMed ID: 24332491
[TBL] [Abstract][Full Text] [Related]
4. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists.
Fu S; Xiang W; Chen J; Ma L; Chen L
Chem Biol Drug Des; 2017 May; 89(5):815-819. PubMed ID: 27779815
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and structure-activity relationships of 3,4,5-trisubstituted 4,5-dihydro-1,2,4-oxadiazoles as TGR5 agonists.
Zhu J; Ye Y; Ning M; Mándi A; Feng Y; Zou Q; Kurtán T; Leng Y; Shen J
ChemMedChem; 2013 Jul; 8(7):1210-23. PubMed ID: 23757200
[TBL] [Abstract][Full Text] [Related]
7. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation.
Scott JS; Birch AM; Brocklehurst KJ; Broo A; Brown HS; Butlin RJ; Clarke DS; Davidsson O; Ertan A; Goldberg K; Groombridge SD; Hudson JA; Laber D; Leach AG; Macfaul PA; McKerrecher D; Pickup A; Schofield P; Svensson PH; Sörme P; Teague J
J Med Chem; 2012 Jun; 55(11):5361-79. PubMed ID: 22545772
[TBL] [Abstract][Full Text] [Related]
8. Discovery and optimization of 5-fluoro-4,6-dialkoxypyrimidine GPR119 agonists.
Buzard DJ; Kim SH; Lehmann J; Han S; Calderon I; Wong A; Kawasaki A; Narayanan S; Bhat R; Gharbaoui T; Lopez L; Yue D; Whelan K; Al-Shamma H; Unett DJ; Shu HH; Tung SF; Chang S; Chuang CF; Morgan M; Sadeque A; Chu ZL; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2014 Sep; 24(17):4332-5. PubMed ID: 25088191
[TBL] [Abstract][Full Text] [Related]
9. Identification of new potent GPR119 agonists by combining virtual screening and combinatorial chemistry.
Wellenzohn B; Lessel U; Beller A; Isambert T; Hoenke C; Nosse B
J Med Chem; 2012 Dec; 55(24):11031-41. PubMed ID: 23211099
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, molecular modeling and biological evaluation of 2-aminomethyl-5-(quinolin-2-yl)-1,3,4-oxadiazole-2(3H)-thione quinolone derivatives as novel anticancer agent.
Sun J; Zhu H; Yang ZM; Zhu HL
Eur J Med Chem; 2013 Feb; 60():23-8. PubMed ID: 23279864
[TBL] [Abstract][Full Text] [Related]
11. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
[TBL] [Abstract][Full Text] [Related]
14. Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists.
Scott JS; Bowker SS; Brocklehurst KJ; Brown HS; Clarke DS; Easter A; Ertan A; Goldberg K; Hudson JA; Kavanagh S; Laber D; Leach AG; MacFaul PA; Martin EA; McKerrecher D; Schofield P; Svensson PH; Teague J
J Med Chem; 2014 Nov; 57(21):8984-98. PubMed ID: 25286150
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915).
Takahashi H; Riether D; Bartolozzi A; Bosanac T; Berger V; Binetti R; Broadwater J; Chen Z; Crux R; De Lombaert S; Dave R; Dines JA; Fadra-Khan T; Flegg A; Garrigou M; Hao MH; Huber J; Hutzler JM; Kerr S; Kotey A; Liu W; Lo HY; Loke PL; Mahaney PE; Morwick TM; Napier S; Olague A; Pack E; Padyana AK; Thomson DS; Tye H; Wu L; Zindell RM; Abeywardane A; Simpson T
J Med Chem; 2015 Feb; 58(4):1669-90. PubMed ID: 25671290
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel series of GPR119 agonists: Design, synthesis, and biological evaluation of N-(Piperidin-4-yl)-N-(trifluoromethyl)pyrimidin-4-amine derivatives.
Kubo O; Takami K; Kamaura M; Watanabe K; Miyashita H; Abe S; Matsuda K; Tsujihata Y; Odani T; Iwasaki S; Kitazaki T; Murata T; Sato K
Bioorg Med Chem; 2021 Jul; 41():116208. PubMed ID: 34010766
[TBL] [Abstract][Full Text] [Related]
17. Oxidative metabolism of a quinoxaline derivative by xanthine oxidase in rodent plasma.
Sharma R; Eng H; Walker GS; Barreiro G; Stepan AF; McClure KF; Wolford A; Bonin PD; Cornelius P; Kalgutkar AS
Chem Res Toxicol; 2011 Dec; 24(12):2207-16. PubMed ID: 21939274
[TBL] [Abstract][Full Text] [Related]
18. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control.
Semple G; Ren A; Fioravanti B; Pereira G; Calderon I; Choi K; Xiong Y; Shin YJ; Gharbaoui T; Sage CR; Morgan M; Xing C; Chu ZL; Leonard JN; Grottick AJ; Al-Shamma H; Liang Y; Demarest KT; Jones RM
Bioorg Med Chem Lett; 2011 May; 21(10):3134-41. PubMed ID: 21444206
[TBL] [Abstract][Full Text] [Related]
19. Structural modifications of N-arylamide oxadiazoles: Identification of N-arylpiperidine oxadiazoles as potent and selective agonists of CB2.
DiMauro EF; Buchanan JL; Cheng A; Emkey R; Hitchcock SA; Huang L; Huang MY; Janosky B; Lee JH; Li X; Martin MW; Tomlinson SA; White RD; Zheng XM; Patel VF; Fremeau RT
Bioorg Med Chem Lett; 2008 Aug; 18(15):4267-74. PubMed ID: 18640038
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationship of dihydrobenzofuran derivatives as novel human GPR119 agonists.
Ye XY; Morales CL; Wang Y; Rossi KA; Malmstrom SE; Abousleiman M; Sereda L; Apedo A; Robl JA; Miller KJ; Krupinski J; Wacker DA
Bioorg Med Chem Lett; 2014 Jun; 24(11):2539-45. PubMed ID: 24755425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
